Ra Pharmaceuticals
Ra Pharmaceuticals

Ra Pharmaceuticals Targeted in $2.1 Billion Acquisition

The global biopharmaceutical company UCB (Brussels: UCB) announced it is acquiring Ra Pharmaceuticals (NASDAQ: RARX) for $2.1 billion. Ra Pharma is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of serious diseases caused by excessive or uncontrolled activation of the complement system, a critical component of the innate immune system. Ra Pharmaceuticals shareholders […]